|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Medical Centre Leeuwarden |
|---|---|
| Information provided by: | Medical Centre Leeuwarden |
| ClinicalTrials.gov Identifier: | NCT00298454 |
Purpose
Intensive care patients with multiple organ dysfunction syndrome often show renal failure with the need for hemofiltration. Resolving renal failure after cessation of hemofiltration may or may not be accompanied by oliguria. Whether or not the administration of diuretics at that moment is appropriate is not known. The study randomises between furosemide or placebo when hemofiltration is stopped. Study endpoint is recovery of renal function.
| Condition | Intervention | Phase |
|---|---|---|
|
Renal Failure Critically Ill |
Drug: Furosemide |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | Forced Diuresis Vs Observation in Resolving Renal Failure After Haemofiltration in Critically Ill Patients (Fodorefh) |
| Estimated Enrollment: | 72 |
| Study Start Date: | December 2005 |
| Study Completion Date: | April 2007 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Netherlands, Fr | |
| Dept of intensive care, Medical Centre Leeuwarden | |
| Leeuwarden, Fr, Netherlands, 8901 BR | |
| Principal Investigator: | Peter van der Voort, MD, PhD, MSc | Dept of intensive care, Medical Centre Leeuwarden, PO Box 888,8901BR Leeuwarden, The Netherlands |
More Information
| Study ID Numbers: | 200601 |
| Study First Received: | March 1, 2006 |
| Last Updated: | April 18, 2007 |
| ClinicalTrials.gov Identifier: | NCT00298454 History of Changes |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
|
renal failure oliguric critically ill furosemide |
|
Disease Attributes Renal Insufficiency Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Diuretics Cardiovascular Agents Furosemide Pharmacologic Actions Membrane Transport Modulators |
Pathologic Processes Urologic Diseases Natriuretic Agents Critical Illness Therapeutic Uses Kidney Diseases Sodium Potassium Chloride Symporter Inhibitors Kidney Failure |